Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Mar 2023
Avascular necrosis (AVN) is considered an iatrogenic complication after treatment for progressive hip dysplasia, but research in China has revealed two characteristics associated with this condition. ossification nuclei.
Read Full NewsA lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.
An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.
1.
HER3 Antibody Drug Conjugate Shows Promise in NSCLC
2.
Novel Agent for Chronic GVHD Wins FDA Approval
3.
Cancer mortality continuing to decline, says report
4.
Increased detection of adenomas may reduce colon cancer risk after colonoscopy in FIT-based screening.
5.
Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.
1.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
2.
Unlocking the Potential of Leukemia Treatment: A New Hope for Patients
3.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
4.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
5.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part XI
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
5.
Navigating the Complexities of Ph Negative ALL - Part IX
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge